Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 9/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 8/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236205 | 0.87 | NPSR1 (0.37) | TLR7ZAP70KARS1ALKKMT2A | |
| SCHEMBL12415767 | 0.86 | ENPP1 (0.38) | ENPP1KMT2A | |
| SCHEMBL13236218 | 0.79 | ALDH1A1 (0.37) | TLR7ZAP70KARS1KMT2ARXFP1 | |
| SCHEMBL12569024 | 0.78 | TBXA2R (0.47) | TLR7ENPP1RXFP1MBOAT4 | |
| SCHEMBL13264578 | 0.75 | ALK (0.30) | TLR7ZAP70KARS1ALK | |
| SCHEMBL1923032 | 0.73 | PTGDR2 (0.39) | KMT2A | |
| SCHEMBL2942781 | 0.73 | PTGDR2 (0.36) | ZAP70KARS1KMT2ARXFP1 | |
| SCHEMBL12568718 | 0.73 | TBXA2R (0.41) | TLR7RXFP1MBOAT4 | |
| SCHEMBL12415741 | 0.72 | PTGDR2 (0.54) | KMT2A | |
| SCHEMBL12415740 | 0.72 | PTGDR2 (0.54) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | TLR7 997/4885ZAP70 2247/4885KARS1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.